Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. 
In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
 

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Expertise France, the French public international cooperation agency, designs and implements projects aligned with the Sustainable Development Goals (SDGs) of the 2030 Agenda and France's external action priorities. Despite progress in poverty reduction and access to health and education, global inequalities persist, exacerbated by climate change and emerging conflicts. In this context, public policies are crucial for sustainable development and inequality reduction.
Supported by UNITAID, Expertise France is implementing the SUCCESS project, which focuses on combating cervical cancer through secondary prevention. The project targets women at high risk, aiming to prevent cancer progression in those with HPV infections and precancerous lesions by improving HPV detection and treatment. SUCCESS is being implemented in Côte d’Ivoire, Burkina Faso, the Philippines, and Guatemala—regions with limited resources where over 85% of cervical cancer deaths occur.